These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12694403)

  • 21. The interaction between human PEX3 and PEX19 characterized by fluorescence resonance energy transfer (FRET) analysis.
    Muntau AC; Roscher AA; Kunau WH; Dodt G
    Eur J Cell Biol; 2003 Jul; 82(7):333-42. PubMed ID: 12924628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A flow cytometric method to detect protein-protein interaction in living cells by directly visualizing donor fluorophore quenching during CFP-->YFP fluorescence resonance energy transfer (FRET).
    He L; Olson DP; Wu X; Karpova TS; McNally JG; Lipsky PE
    Cytometry A; 2003 Oct; 55(2):71-85. PubMed ID: 14505312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agonist-induced internalization of human ml muscarinic receptor mutants: immunofluorescence confocal microscopy.
    Arden J; Lameh J
    Proc West Pharmacol Soc; 1996; 39():51-4. PubMed ID: 8895968
    [No Abstract]   [Full Text] [Related]  

  • 24. Intramolecular interactions in muscarinic acetylcholine receptors studied with chimeric m2/m5 receptors.
    Pittel Z; Wess J
    Mol Pharmacol; 1994 Jan; 45(1):61-4. PubMed ID: 8302281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemical synthesis of MT1 and MT7 muscarinic toxins: critical role of Arg-34 in their interaction with M1 muscarinic receptor.
    Mourier G; Dutertre S; Fruchart-Gaillard C; Ménez A; Servent D
    Mol Pharmacol; 2003 Jan; 63(1):26-35. PubMed ID: 12488533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of an in situ disulfide cross-linking strategy to map proximities between amino acid residues in transmembrane domains I and VII of the M3 muscarinic acetylcholine receptor.
    Hamdan FF; Ward SD; Siddiqui NA; Bloodworth LM; Wess J
    Biochemistry; 2002 Jun; 41(24):7647-58. PubMed ID: 12056896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling of the binding site of the human m1 muscarinic receptor: experimental validation and refinement.
    Bourdon H; Trumpp-Kallmeyer S; Schreuder H; Hoflack J; Hibert M; Wermuth CG
    J Comput Aided Mol Des; 1997 Jul; 11(4):317-32. PubMed ID: 9334899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor.
    Jakubík J; Tucek S; El-Fakahany EE
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1033-41. PubMed ID: 12023535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Site-directed mutagenesis of m1-toxin1: two amino acids responsible for stable toxin binding to M(1) muscarinic receptors.
    Krajewski JL; Dickerson IM; Potter LT
    Mol Pharmacol; 2001 Oct; 60(4):725-31. PubMed ID: 11562434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of MT7 toxin on the oligomerization state of the M1 muscarinic receptor.
    Marquer C; Fruchart-Gaillard C; Mourier G; Grandjean O; Girard E; le Maire M; Brown S; Servent D
    Biol Cell; 2010 Apr; 102(7):409-20. PubMed ID: 20170475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.
    Buckley NJ; Bonner TI; Buckley CM; Brann MR
    Mol Pharmacol; 1989 Apr; 35(4):469-76. PubMed ID: 2704370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological characterization of human m1 muscarinic acetylcholine receptors with double mutations at the junction of TM VI and the third extracellular domain.
    Huang XP; Williams FE; Peseckis SM; Messer WS
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1129-39. PubMed ID: 9732369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Site-directed mutagenesis implicates a threonine residue in TM6 in the subtype selectivities of UH-AH 37 and pirenzepine at muscarinic receptors.
    Ellis J; Seidenberg M
    Pharmacology; 2000 Aug; 61(2):62-9. PubMed ID: 10940778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors.
    Ziegler N; Bätz J; Zabel U; Lohse MJ; Hoffmann C
    Bioorg Med Chem; 2011 Feb; 19(3):1048-54. PubMed ID: 20716489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A chimeric D2 dopamine/m1 muscarinic receptor with D2 binding specificity mobilizes intracellular calcium in response to dopamine.
    England BP; Ackerman MS; Barrett RW
    FEBS Lett; 1991 Feb; 279(1):87-90. PubMed ID: 1995348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple binding affinities of N-methylscopolamine to brain muscarinic acetylcholine receptors: differentiation from M1 and M2 receptor subtypes.
    el-Fakahany EE; Ramkumar V; Lai WS
    J Pharmacol Exp Ther; 1986 Aug; 238(2):554-63. PubMed ID: 3755473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile.
    Dautzenberg FM; Kilpatrick GJ; Wille S; Hauger RL
    J Neurochem; 1999 Aug; 73(2):821-9. PubMed ID: 10428081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Miniaturization of fluorescence polarization receptor-binding assays using CyDye-labeled ligands.
    Harris A; Cox S; Burns D; Norey C
    J Biomol Screen; 2003 Aug; 8(4):410-20. PubMed ID: 14567793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function.
    Ward SD; Curtis CA; Hulme EC
    Mol Pharmacol; 1999 Nov; 56(5):1031-41. PubMed ID: 10531410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of the rate of muscarinic M1 receptor plasma membrane delivery using a regulated secretion/aggregation system.
    Sawyer GW; Ehlert FJ; Hart JP
    J Pharmacol Toxicol Methods; 2006; 53(3):219-33. PubMed ID: 16213169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.